ANGOAngioDynamics, Inc.
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates…
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
Older | ||
 AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | ||
 AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 AngioDynamics (NASDAQ:ANGO) expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat | ||
 Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure? AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain. | ||
 ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins. | ||
 ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going? AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high. | ||
 AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript Med Tech revenue surged 16.7% as company shifts toward higher-margin products. | ||
 AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus. | ||
 AngioDynamics, Inc. Q4 2026 Earnings Call Summary Moby summary of AngioDynamics, Inc.'s Q4 2026 earnings call | ||
AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges AngioDynamics Inc (ANGO) reports robust revenue increases driven by MedTech and NanoKnife segments, despite facing net losses and competitive market pressures. | ||
 AngioDynamics Q4 Earnings Call Highlights AngioDynamics (NASDAQ:ANGO) reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation. On the company’s fisc | ||
 AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates AngioDynamics (ANGO) delivered earnings and revenue surprises of +36.36% and +7.61%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 AngioDynamics Tops Revenue Forecasts and Raises Sales Outlook for Fiscal 2027 (ANGO) AngioDynamics Inc. (NASDAQ:ANGO) delivered stronger-than-expected fourth-quarter results on Tuesday, beating Wall Street forecasts for both revenue and adjusted earnings while issuing an upbeat sales outlook for fiscal 2027. | ||
AngioDynamics: Fiscal Q4 Earnings Snapshot LATHAM, N.Y. (AP) — AngioDynamics Inc. (ANGO) on Tuesday reported a loss of $11.4 million in its fiscal fourth quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 27 cents. For the year, the company reported that its loss widened to $36.7 million, or 88 cents per share. | ||